AbbVie Inc. EBIT

EBIT of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including EBIT growth rates and interactive chart. Earnings before interest and taxes is an indicator of a company's profitability. One can calculate it as revenue minus all expenses, excluding tax and interest. EBIT is also referred to as operating earnings, operating profit, and profit before interest and taxes. It is the amount of profit that a company earns before interest on debt and taxes are paid.

Highlights and Quick Summary

  • EBIT for the quarter ending September 29, 2020 was $3.26 Billion (a 332.85% increase compared to previous quarter)
  • Year-over-year quarterly EBIT decreased by -17.72%
  • Annual EBIT for 2019 was $13 Billion (a 103.4% increase from previous year)
  • Annual EBIT for 2018 was $6.38 Billion (a -33.13% decrease from previous year)
  • Annual EBIT for 2017 was $9.55 Billion (a 2.19% increase from previous year)
  • Twelve month EBIT ending September 29, 2020 was $11.6 Billion (a 5.84% increase compared to previous quarter)
  • Twelve month trailing EBIT decreased by -10.91% year-over-year
Trailing EBIT for the last four month:
29 Sep '20 29 Jun '20 30 Mar '20 30 Dec '19
$11.6 Billion $10.9 Billion $13.6 Billion $13 Billion
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EBIT of AbbVie Inc.

Most recent EBITof ABBV including historical data for past 10 years.

Interactive Chart of EBIT of AbbVie Inc.

AbbVie Inc. EBIT for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $3,255.0 $752.0 $3,603.0
2019 $3,956.0 $2,617.0 $3,400.0 $3,010.0 $12,983.0
2018 $-2,441.0 $3,159.0 $2,762.0 $2,903.0 $6,383.0
2017 $1,782.0 $2,694.0 $2,662.0 $2,407.0 $9,545.0
2016 $2,314.0 $2,361.0 $2,387.0 $2,278.0 $9,340.0
2015 $2,113.0 $1,885.0 $1,852.0 $1,687.0 $7,537.0
2014 $-415.0 $960.0 $1,515.0 $1,351.0 $3,411.0
2013 $1,535.0 $1,371.0 $1,453.0 $1,305.0 $5,664.0
2012 $1,821.0 $1,596.0 $1,422.0 $978.0 $5,817.0
2011 $-5,886.69 $4,409.0 $4,274.0 $824.44 $3,620.0
2010 $4,717.0

Business Profile of AbbVie Inc.

Sector: Healthcare
Industry: Drug Manufacturers—General
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides SYNAGIS that protects at-risk infants from severe respiratory disease; KALETRA, a prescription anti-HIV-1 medicine; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; and Lupron, a product for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; and Sevoflurane, an anesthesia product. It has collaborations with Calico Life Sciences LLC; Alector, Inc.; Janssen Biotech, Inc.; Frontier Medicines, Corp.; Jacobio Pharmaceuticals; I-Mab; and Genmab A/S. The company was incorporated in 2012 and is based in North Chicago, Illinois.